Introduction: Early-onset Schizophrenia (EOS) is a rare and severe condition. A higher rate of neurodevelopmental abnormalities, such as intellectual or communication impairments as well as attention deficit hyperactivity disorder, is observed in EOS compared to adult-onset schizophrenia. Early signs of autism spectrum disorders (ASD) are present in about 30% of patients with EOS. Genetic abnormalities, including copy number variations, are frequent in neurodevelopmental disorders and have been associated to ASD physiopathology. Implicated genes encode proteins involved in brain development, synapses morphology and plasticity and neurogenesis. In addition, an increasing number of genetic abnormalities are shared by EOS and ASD, underlying the neurodevelopmental hypothesis of EOS.
AUTHORS and AFFILIATIONS
Safety. All patients, their parents and siblings signed informed consent upon enrolment in the study. Results of the present study should help to unravel the molecular pathology of EOS, paving the way for an early therapeutic intervention.
Trial registration number: NCT02565524
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Strengths and limitations of this study
• University Child Psychiatry Department has recognized specialists in rare and severe disorders such as Early-Onset Schizophrenia (EOS).
• Innovative clinical research protocol in the field of child psychiatry associating psychiatric assessments, neuropsychological explorations and DNA next generation sequencing of patients as well as their parents and siblings.
• Collaboration with research may provide new understanding of the molecular mechanisms of the condition and could provide biomarkers for diagnosis and treatment.
• Clinical research very challenging in EOS patients and families (severity of illness and impact on individual and family life), with limited sample size (rare condition, regional enrolment) and difficulties in involving both parents (separation, conflict, death ).
• Exome analysis may miss causative mutations in non-coding part of the genome. (delusions, hallucinations, and disorganized speech or behavior) before the age of 18 [1, 2] . Onset before 13 years of age is called Childhood-Onset Schizophrenia (COS) [3, 4] .
A higher rate of neurodevelopmental abnormalities is observed in EOS compared to Adult-Onset Schizophrenia (AOS), and patients typically have frequent deficits in cognition, communication or neuromotor impairments associated with attention deficit, hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) [5] [6] [7] . Furthermore, 28% of patients with COS in the US cohort of the National Institute of Mental Health Child Psychiatry Branch met criteria for comorbid ASD [6] , and more than 80% of children with schizophrenia or schizoaffective disorder might present comorbid ADHD [7] . In addition, EOS (including COS) is a complex disorder related to other neurodevelopmental disorders, and it represents a real challenge for clinical diagnosis [8] with, to date, no objective test based on genetics. Therefore, it is critical to conduct a rigorous and homogeneous phenotypic characterization by using international classifications such as ICD or DSM [9] [10] [11] and by using standardized and internationally validated psychiatric categorical assessments.
A few genetic studies of EOS are reported, due to the very low prevalence [1, 2] and to the nosographic difficulties which made it difficult to obtain a consensual clinical definition of this disorder and to carry out etiological studies. Interestingly, DSM-5 classification provides clarification in this area with schizophrenia no longer excluding the diagnosis of ASD and formalizing the overlap between these two Submicroscopic cytogenetic abnormalities, such as disease-related Copy Number Variations (CNVs), are more frequent in COS than in AOS (about 11% [12, 13] vs 2-5%, p<0.0001 [13] ). A high heritability rate of COS (>80%) has also been suggested in early adoption/twin studies and has been confirmed by familial aggregation studies [14, 15] . The fact that genome-wide association studies (GWASs) failed to yield a genome-wide significant result in AOS patients appears to argue in favor of a polygenic basis of EOS with hundreds of genes with small individual effects being involved [16] . In EOS pathogeny, recent studies also demonstrated the involvement of mutations in NRXN1 (2p16.3) and UPF3B (Xq24),
crucial for development and function of the brain [13, 17] .
Next generation sequencing (NGS) is a process to determine the entire DNA sequence of a given individual with unprecedented throughput, scalability and speed.
Whole-exome sequencing (WES), a NGS method, corresponds to an exhaustive analysis of the exome (the coding part of the genome) thus helping to understand complex neurodevelopmental disorders such as EOS [18] . To our knowledge, until now, only two studies using WES have been published in the field of EOS.
SMEDEMARK-MARGULIES and colleagues described de novo heterozygous 
METHODS AND ANALYSIS

Objectives
The main objective of this study is to identify disease causing mutations primarily in genes involved in neurodevelopmental pathways in a cohort of patients affected by EOS.
The secondary objectives are the characterization of the clinical and neurocognitive profiles of patients and their first-degree relatives.
Trial design
GenAuDiss is a translational multicenter study. Patients with EOS were initially recruited through the 2011-2013 Interregional Hospital Clinical Research Program (NCT01512641) whose main goal was to estimate the prevalence of dissociative disorders in a population of children in child psychiatry care or medico-education structures. A total of six patients and 14 first-degree relatives have been enrolled from this completed program. In addition, an enrolment in the present study is offered to in-and out-patients corresponding to the inclusion criteria of the investigator, Child and Adolescent Psychiatry (CAP) centers, as well as their first-degree relatives.
Participants are included either directly at the study sites or after referral by child and adolescent psychiatrists of the Provence-Alpes-Côte d'Azur (PACA) region. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Inclusion criteria
The study is proposed to children and adolescents presenting EOS with co-morbid ASD, and their first-degree relatives.
Major inclusion criteria for patients:
• Age of 7 to 22 years;
• Diagnosis of early-onset schizophrenia (onset before age 18), diagnosed by the semi-structured interview Kiddie Schedule for Affective Disorders and
Schizophrenia -Present and Lifetime Version (K-SADS-PL) psychosis section
[22];
• Diagnosis of Autism Spectrum Disorder (ASD) (Autism Diagnostic interview-
• Intelligence quotient (IQ) ≥ 50 at Wechsler Intelligence Scale for Children
Major inclusion criteria for parents and siblings:
• First degree biological relationship (no adoption) with the index patient. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y
Exclusion criteria
• Refusal or withdrawal of consent;
• Children without verbal language;
• Adults protected by law (relatives).
Measures
Quantitative and qualitative measures are assessed during the study (summarized in Table 1 ):
• Clinical parameters from medical history (including pregnancy, birth, etc.) and biographic parameters, types and dates of significant life events including trauma and environmental exposures (e. g., drugs and substances);
• Clinical parameters from physical examination (e. g., body weight, BMI, arterial pressure);
• Semistructured interviews to assess main diagnosis at inclusion (K-SADS-PL, MINI, ADI-R) [22, 23, 26, 27 ];
• Clinical heteroassessments with specific rating scales (WISC IV or V, PANSS, SANS, TMTA, TMTB, Verbal fluency) [24, 25, 28, 29 ];
• Self-report questionnaires (Cloninger's TCI 226, Baron Cohen's AQ) [30, 31, 32 ];
• Genetic analysis (including DNA testing for fragile-X syndrome, high resolution karyotype, DNA CNVs from CGH array, DNA SNPs from exome sequencing).
Data collection process
Each investigator at study sites is responsible for collecting and entering data on the CRF paperwork at the time of the visit and for realizing quality check of the data and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 be calculated. Categorical data will be presented by means of frequency (n, %).
Changes in the parameters and in the distribution of categorical variables from baseline to follow-up points will be tested with univariate analysis using appropriate testing according to the type of variable and distribution. In addition, multivariate analysis will be carried out to investigate putative relationships between variables.
Level of significance for the p value was fixed at <0.05.
Outcomes
The main objective is to expand the repertoire of the genetic abnormalities associated to EOS phenotypes by performing:
• WES on trio (mother, father and child);
• Bioinformatics analysis and variant prioritization using validated tools (RVIS and Polyphen2) [33, 34] and strategies in accordance with international guidelines [35] . Clinical profile:
• K-SADS-PL [22] for DSM IV-TR / DSM-5 co-morbid psychiatric diagnosis of patients and minor siblings;
• MINI assessments for DSM IV-TR / DSM 5 psychiatric diagnosis of parents and major siblings [26];
• Evaluation of the intensity of positive and negative symptoms, general psychopathology and subtypes of schizophrenia using PANSS/SANS [28, 29] ;
• Personality dimensional test using computerized version of TCI 226
(Cloninger) in parents [30, 31] ;
• Autistic traits using AQ (Baron-Cohen) in siblings and parents [32] .
Neurocognitive profile:
• Evaluation of executive and attentional functions of patients using Trail Making Test (TMT) A and B and verbal fluency;
• Wechsler Intelligence Scale for Children (WISC) IV or V [24, 25] , full version in patient and WISC IV abridged version in minor siblings; Wechsler Adult
Intelligence Scale-III (WAIS III) in a short form in adult siblings and parents [36, 37] .
DISCUSSION
This project is based on a translational cross-sectional study protocol that aims to gain further understanding of the pathogenic molecular mechanisms of EOS. In fact, even if genomics is more and more often used for the diagnosis of human diseases including psychiatry [38] , the pathophysiology of EOS still needs to be elucidated. 
Competing interests statement
The authors declare no conflict of interest. The main objective of our study is to identify disease-causing genetic mutations in a cohort of patients affected by both EOS and ASD. Special attention will be paid to genes involved in neurodevelopmental pathways.
Methods and analysis:
We describe a multi-centric study in a paediatric population.
The study started in April 2014. Inclusion criteria are: age 7 to 22 years, diagnosis of EOS with co-morbid ASD and IQ above 50; Parents and siblings are also enrolled.
We perform psychiatric assessments (MINI, K-SADS-PL, PANSS, SANS) together with neurocognitive evaluations (IQ, TMT A/B, verbal fluency). Then, we study
variants of the coding part of DNA (exome), using next generation sequencing (NGS) process on trio (mother, father, child). Bio-informatics tools (RVIS, PolyPhen-2) are used to prioritize disease-causing mutations in candidate genes. The inclusion period will end in November 2019. 
Strengths and limitations of this study
• Exome analysis may miss causative mutations in non-coding part of the genome. 
METHODS AND ANALYSIS
Objectives
Trial design
GenAuDiss is a translational multicenter study. Patients with EOS were initially The investigator centers of the GenAuDiss are the Children's Hospitals of Nice CHULenval, the Marseille University Hospital, the Hospital La Fontonne (Antibes) and the 
Inclusion criteria
Schizophrenia -Present and Lifetime Version (K-SADS-PL) psychosis section;
• Diagnosis of Autism Spectrum Disorder (ASD) (Autism Diagnostic interviewRevised (ADI-R);
• Intelligence quotient (IQ) ≥ 50 at Wechsler Intelligence Scale for Children (WISC IV, abridged version).
• First degree biological relationship (no adoption) with the index patient.
Exclusion criteria
• Children without verbal language; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y
Measures
• Semistructured interviews to assess main diagnosis at inclusion (K-SADS-PL • Genetic analysis (including DNA testing for fragile-X syndrome, high resolution karyotype, DNA CNVs from CGH array, DNA SNPs from exome sequencing).
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Data collection process
Each investigator at study sites is responsible for collecting and entering data on the CRF paperwork at the time of the visit and for realizing quality check of the data and regulation requirements. Results will be manually entered in the database by the clinical research assistants at the main investigator study center. In order to avoid missing data or filling errors, a double-check will be carried out before freezing of the database. Data extraction and analysis of the database will be performed by the
Department of Clinical Research and Innovation (DRCI) of the Nice University
Hospital.
Statistical analysis
Statistical analysis will be conducted by the DRCI of the Nice University Hospital. A descriptive analysis of all collected parameters will be performed. For continuous variables (e. g., age, weight), indicators such as the mean, SD and range values will be calculated. Categorical data will be presented by means of frequency (n, %).
Outcomes
• WES on trio (mother, father and child); The secondary objectives of the GenAuDiss study are the characterization of the clinical and neurocognitive profile of patients and their first-degree relatives.
Clinical profile:
• K-SADS-PL for DSM IV-TR / DSM-5 co-morbid psychiatric diagnosis of patients and minor siblings;
• MINI assessments for DSM IV-TR / DSM 5 psychiatric diagnosis of parents and major siblings;
• Evaluation of the intensity of positive and negative symptoms, general psychopathology and subtypes of schizophrenia using PANSS/SANS;
• Personality dimensional test using computerized version of TCI 226 (Cloninger) in parents;
• Autistic traits using AQ (Baron-Cohen) in siblings and parents.
• Wechsler Intelligence Scale for Children (WISC) IV or V, full version in patient and WISC IV abridged version in minor siblings; Wechsler Adult Intelligence Scale-III (WAIS III) in a short form in adult siblings and parents [36, 37] .
Patient and Public Involvement
Results will systematically be transmitted with patients and legal caregivers. Results will also be discussed with the referent psychiatrist of child psychiatry care and/or Furthermore, the known genetic heterogeneity of adult onset schizophrenia spectrum disorders imposes to build up models that consider the interplay between several factors. In fact, the "two-hit" hypothesis proposes to consider the impact of at least two genetic or clinical factors (CNV + CNV, CNV + SPN or CNV + epigenetic impact of trauma, etc.) [40] .
Perspectives
Mutated genes will be classified according to their pathogenic level, and the most likely disease causing candidate mutations will be studied by a research team expert in neuroscience (Laboratory "RNA Metabolism and Neurodevelopmental Disorders", Dr. Barbara Bardoni, IPMC, CNRS, France). Further study of gene expression levels and in vivo cell activity in animal models will help predict the impact of the mutation on the protein structure and function. Finally, better understanding of EOS 
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